Reference drug
Phase 1Small molecule
Chong Kun Dang PharmaceuticalReference drug is one of 38 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 1.
1
Indications
15
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
130 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Lescol
NovartisPhase 3
Micardis
Boehringer IngelheimPhase 3
Comparator: Statins
Merck & Co.Phase 3
Statin
Bristol-Myers SquibbPhase 3
Evacetrapib
Eli LillyPhase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Enlicitide
Merck & Co.Phase 3
Anacetrapib
Merck & Co.Phase 3
Lapaquistat Acetate
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
CKD5 trials
Adult2 trials
Randomized1 trial
MPA1 trial
5 more indications
Pilot Study1 trial
Fasting Conditions1 trial
Hypercholesterolemia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reference drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details